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Background. CD4 count at start of combination antiretroviral therapy (ART) is strongly associated with short-term survival, but
its association with longer-term survival is less well characterized.
Methods. We estimated mortality rates (MRs) by time since start of ART (<0.5, 0.5–0.9, 1–2.9, 3–4.9, 5–9.9, and ≥10 years)
among patients from 18 European and North American cohorts who started ART during 1996–2001. Piecewise exponential models
stratiﬁed by cohort were used to estimate crude and adjusted (for sex, age, transmission risk, period of starting ART [1996–1997,
1998–1999, 2000–2001], and AIDS and human immunodeﬁciency virus type 1 RNA at baseline) mortality rate ratios (MRRs) by
CD4 count at start of ART (0–49, 50–99, 100–199, 200–349, 350–499, ≥500 cells/µL) overall and separately according to time since
start of ART.
Results. A total of 6344 of 37 496 patients died during 359 219 years of follow-up. The MR per 1000 person-years was 32.8 (95%
conﬁdence interval [CI], 30.2–35.5) during the ﬁrst 6 months, declining to 16.0 (95% CI, 15.4–16.8) during 5–9.9 years and 14.2
(95% CI, 13.3–15.1) after 10 years’ duration of ART. During the ﬁrst year of ART, there was a strong inverse association of CD4 count
at start of ART with mortality. This diminished over the next 4 years. The adjusted MRR per CD4 group was 0.97 (95% CI, .94–1.00;
P = .054) and 1.02 (95% CI, .98–1.07; P = .32) among patients followed for 5–9.9 and ≥10 years, respectively.
Conclusions. After surviving 5 years of ART, the mortality of patients who started ART with low baseline CD4 count converged
with mortality of patients with intermediate and high baseline CD4 counts.
Keywords. HIV; CD4 count; antiretroviral therapy; mortality; cohort collaboration.
Combination antiretroviral therapy (ART) based on ≥3 antire-
troviral drugs including either a protease inhibitor (PI), nonnu-
cleoside reverse transcriptase inhibitor (NNRTI), or integrase
inhibitor has substantially improved the prognosis of human
immunodeﬁciency virus type 1 (HIV-1)–infected patients
since its introduction in high-income settings in 1996 [1].
ART suppresses HIV-1 replication, leading to declines in plas-
ma HIV-1 RNA, increased CD4 T-cell counts, and, eventually,
decreased morbidity and mortality [2]. Because patients have
now been treated with ART for up to 20 years, it is of major in-
terest to explore predictors of long-term prognosis.
The Antiretroviral Therapy Cohort Collaboration (ART-CC)
was initiated in 2000 by investigators from HIV cohort studies
in North America and Europe, to assemble datasets that were
sufﬁciently large to study the prognosis of HIV-1–infected
patients who started ART. Prognostic models that estimated
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3- and 5-year survival were published in 2002 and 2007 [3, 4]
and showed CD4 count at start of ART (baseline) to be the
strongest predictor of short-term mortality. However, baseline
CD4 count becomes less prognostic when 6-month response
to treatment is taken into account [5]. HIV-1 RNA load at 6
months and changes in CD4 count from 6 to 36 months after
start of ART are prognostic for AIDS in patients who have sur-
vived 3 years of ART [6].
To date, short-term prognosis has been extrapolated to pre-
dict long-term disease-free survival [7, 8]. Because mortality in
the general population varies by age, sex, and country of resi-
dence, estimates of mortality rate ratios (MRRs) may be more
informative when corrected for background mortality [9]. We
investigated how long patients bear the burden of increased
mortality due to starting ARTwith low CD4 counts, by studying
the prognostic value of baseline CD4 count for mortality up to
15 years after start of ART, using both standard survival analysis
models and models for relative survival.
METHODS
Study Sample
The ART-CC, which is described in detail elsewhere (http://www.
art-cohort-collaboration.org) [10], is an international collabora-
tion of HIV cohort studies from North America and Europe that
combines data on HIV-infected individuals aged ≥16 years who
were antiretroviral-naive when they started ART with a combina-
tion of at least 3 drugs. Eligible regimens include at least 1 PI,
NNRTI, or integrase inhibitor and 2 nucleoside-analogue reverse
transcriptase inhibitors (NRTIs). The present study included data
from 18 cohorts, which are listed in the Supplementary Appen-
dix. All were approved by local ethics committees. The National
Health Service Health Research Authority South West–Cornwall
and Plymouth Research Ethics Committee, United Kingdom, ap-
proved the study (REC reference 12/SW/0253). The data used
here included follow-up from 1996 until 31 July 2013.We includ-
ed patients who started ART between 1996 and 2001 (so had at
least 12 years of potential follow-up) and had at least 1 available
baseline (within 3 months prior to starting ART) measurement
of CD4 count and viral load.
Statistical Analysis
We categorized CD4 counts into 6 groups (0–49, 50–99, 100–
199, 200–349, 350–499, and ≥500 cells/µL); viral loads into 3
groups (0–9999, 10 000–99 999, and ≥100 000 copies/µL); age
at baseline into 5 groups (16–29, 30–39, 40–49, 50–59, and
≥60 years); year of starting ART into 3 groups (1996–1997,
1998–1999, and 2000–2001); and ART regimen into 5 groups
(NNRTI-based, PI-based, NRTI including abacavir, other
NRTI not including abacavir, and other regimens). Patients
were followed up from the date of starting ART (“baseline”)
to the earliest of the date of death, loss to follow-up, or admin-
istrative censoring. Patients were considered lost to follow-up at
their last clinical observation if it was more than a year before
the cohort-speciﬁc close date of the database. Data were ana-
lyzed as intent to continue treatment, ignoring treatment
changes and interruptions.
We used unadjusted (Kaplan–Meier) and adjusted estimates
of cumulative mortality to examine whether CD4 count at start
of ART was prognostic for mortality. The adjusted estimates
were for a typical patient: men who have sex with men (MSM)
aged 30–39 years, who started ART between 1998 and 1999 in
the French Hospital Database on HIV (FHDH) cohort with-
out a diagnosis of AIDS, and with high viral load (HIV-1
RNA > 100 000 copies/µL). We used Poisson models to estimate
crude mortality rates (MRs) with 95% conﬁdence intervals
(CIs), for all patients and by baseline CD4 count. We then es-
timated MRs separately according to duration of time on ART
(<0.5, 0.5–0.9, 1–2.9, 3–4.9, 5–9.9, and ≥10 years after ART
start), overall, and by baseline CD4 count. We used Cox models
stratiﬁed by cohort to estimate crude and adjusted (for sex, age,
transmission risk group, AIDS at baseline, baseline viral load,
and year of starting ART) MRRs by baseline CD4 group with
200–349 cells/µL as the reference category, overall and sepa-
rately according to time on ART. Relative survival models
based on generalized linear models (modiﬁed Poisson models)
were used to account for variation in background population
mortality [11]. Expected death rates for each country split by
sex and 5-year age group were obtained from the Human Mor-
tality Database (www.mortality.org). We estimated adjusted
(for the same set of covariates) relative MRR, overall and ac-
cording to duration of time on ART. The prognostic value of
baseline CD4 count according to time since start of ART was
compared by estimating the adjusted MRR per CD4 count cat-
egory (assuming a log-linear relationship with MR across the
CD4 categories). All analyses were performed using Stata soft-
ware version 13 (StataCorp, College Station, Texas).
RESULTS
A total of 37 496 patients started ART between 1996 and 2001
and were eligible for analyses. The majority were male, with a
median age at start of ART of 37 years (interquartile range
[IQR], 31–44 years; Table 1). Median follow-up time was 11.3
years (IQR, 5.6–13.4 years), with 28 947 (77%) of patients hav-
ing at least 5 years and 21 936 (58%) >10 years’ follow-up.
Numbers of patients at risk by duration of ART and baseline
CD4 count are shown in Supplementary Table 1. The risk trans-
mission group distribution reﬂected the early HIV epidemic,
with similar proportions of MSM and heterosexually infected
patients, and 20% infected via injection drug use. The median
baseline CD4 count was 221 cells/µL (IQR, 86–376 cells/µL):
17 077 (46%) patients started ART with CD4 count
<200 cells/µL and 10 278 (27%) with CD4 count <100 cells/µL.
Compared with patients who started ART with CD4 count
<350 cells/µL, those who started with higher CD4 count were
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more likely to be MSM and to have started ART in 1997–1999,
and were slightly younger on average. The majority of patients
(24 313 [65%]) started on a PI-based regimen, whereas 10 146
(27%) started on an NNRTI-based regimen. The rate of loss to
follow-up was 0.04 per year.
There were 6344 deaths during 359 219 years of follow-up.
Baseline CD4 count was highly prognostic for unadjusted cu-
mulative mortality in all patients (Figure 1). Baseline CD4 count
was also highly prognostic for adjusted cumulative mortality,
which is illustrated for a typical patient group (MSM in the
FHDH cohort, aged 30–39 years, who started ART between
1998 and 1999 without a diagnosis of AIDS, and with high
viral load [HIV-1 RNA > 100 000 copies/µL]) in Figure 2.
There is a clearly graded increase in mortality with decreasing
baseline CD4 count: Cumulative 15-year mortality varied from
7.1% (95% CI, 2.9%–11.3%) for baseline CD4 count >500 cells/
µL to 10.7% (95% CI, 4.7%–16.7%) for baseline CD4 count <50
cells/µL. A table showing the corresponding numbers at risk for
Figure 1 at different time-points split by CD4 count is available
from the authors on request.
Numbers of deaths and crude MRs per 1000 person-years,
according to baseline CD4 count and time since start of ART,
Figure 2. Adjusted estimates of cumulative mortality by CD4 cell count at start of
antiretroviral therapy (ART) for a typical patient group (men who have sex with men,
aged 30–39 years, who started ART between 1998 and 1999 without a diagnosis of
AIDS, with high viral load [human immunodeficiency virus {HIV}-1 RNA > 100 000 cop-
ies/µL]) from the French Hospital Database on HIV cohort.
Table 1. Demographic and Clinical Characteristics at Start of
Antiretroviral Therapy (N = 37 496)
Characteristic
No. of Patients
(%)
No. of Deaths
(%)
Year of starting ART
1996–1997 8304 (22) 1550 (19)
1998–1999 15 599 (42) 2760 (18)
2000–2001 13 593 (36) 2034 (15)
Female sex 8293 (22) 817 (10)
AIDS at start of ART 8516 (23) 2103 (25)
CD4 count, cells/µL
Median (IQR) 221 (86–376)
0–49 6512 (17) 1654 (25)
50–99 3766 (10) 844 (22)
100–199 6799 (18) 1292 (19)
200–349 9633 (26) 1338 (14)
350–499 5990 (16) 697 (12)
≥500 4796 (13) 519 (11)
HIV-1 RNA, copies/µL
Median (IQR) 75 000 (18 000–239 000)
0–9999 6834 (18) 843 (12)
10 000–99 999 14 149 (38) 2 186 (15)
≥100 000 16 513 (44) 3315 (20)
Age, y
Median (IQR) 37 (31–44)
16–29 6734 (18) 514 (8)
30–39 16 572 (44) 2094 (13)
40–49 9104 (24) 1989 (22)
50–59 3766 (10) 1184 (31)
≥60 1320 (4) 563 (43)
Risk transmission group
MSM 11 067 (30) 1056 (10)
Injection drug use 7626 (20) 1625 (21)
Heterosexual 11 709 (31) 1122 (10)
Blood 440 (1) 77 (18)
Other or unknown 6654 (18) 2464 (37)
Length of follow-up, y, median
(IQR)
11.3 (5.6–13.4)
Regimen
NNRTI-based 10 146 (27) 1559 (15)
PI-based 24 313 (65) 4371 (18)
Triple NRTI (including abacavir) 2006 (5) 240 (12)
Other-NRTI 760 (2) 112 (15)
Other 271 (1) 62 (23)
Abbreviations: ART, antiretroviral therapy; HIV-1, human immunodeficiency virus type 1;
IQR, interquartile range; MSM, men who have sex with men; NNRTI, nonnucleoside
reverse transcriptase inhibitor; NRTI, nucleoside-analogue reverse transcriptase inhibitor;
PI, protease inhibitor.
Figure 1. Unadjusted estimates of overall cumulative mortality by CD4 cell count
at start of antiretroviral therapy (ART).
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are shown in Table 2. Overall mortality per 1000 person-years
declined from 33 (95% CI, 30–36) during the ﬁrst 6 months of
ART to 14 (95% CI, 13–15) among those who survived 10
years from start of ART, despite the aging of the study popu-
lation over this period. Patients who started ART with a CD4
count <50 cells/µL experienced the greatest declines in MRs
over time on ART, from 88 (95% CI, 78–99) per 1000 person-
years during the ﬁrst 6 months to 15 (95% CI, 13–17) per
1000 person-years after 10 years from start of ART. Although
MRs were strongly inversely associated with baseline
CD4 counts at shorter times since start of ART, the magni-
tude of these associations diminished with increasing dura-
tion of ART. Beyond 10 years of ART, there was little evidence
of differences in crude MRs according to CD4 count at start
of ART.
Table 3 shows associations of CD4 count at start of ART with
mortality at different durations since start of ART and averaged
over all follow-up time, estimated from crude, adjusted, and rel-
ative survival models. Estimates are presented as MRRs with 95%
CIs, with CD4 count 200–349 cells/µL as the comparator group.
As expected crude, adjusted, and relative MRRs averaged over all
follow-up time decreased with increasing CD4 count at start of
ART. After adjusting for other prognostic factors, the MRR com-
paring baseline CD4 count <50 cells/µL with 200–349 cells/µL
during the ﬁrst 6 months of ART was 2.81 (95% CI, 2.12–
3.71): this declined to 1.59 (95% CI, 1.31–1.92) 3–4.9 years
after start of ART. During the ﬁrst 5 years of ART, rate ratios
comparing patients whose baseline CD4 count was >350 cells/
µL with those whose count was 200–349 cells/µL were <1. How-
ever, there was little evidence that baseline CD4 count was prog-
nostic for mortality after 5 years of ART as the adjusted MRRs
per CD4 category were 0.97 (95% CI, .94–1.00; P = .054) and
1.02 (95% CI, .98–1.07; P = .32) among patients followed for 5–
9.9 and≥10 years, respectively. Adjusted relative MRRs were gen-
erally further from 1 than the corresponding adjusted MRRs,
indicating that failing to account for expected mortality partially
obscured the association of CD4 count with mortality risk. Dif-
ferences between the 2 analyses diminished with increasing time
on ART because the strength of the association of mortality with
baseline CD4 count also decreased with time.
DISCUSSION
In our collaborative analysis of 37 496 HIV-infected patients
from 18 cohorts starting triple-combination ART between 1996
and 2001, there was a strong inverse association of CD4 count
with mortality during the ﬁrst year of ART, which diminished
over the next 4 years. From 5 years after start of ART, baseline
CD4 count was of little prognostic value. Even patients who start-
ed ART with very low (<50 cells/µL) CD4 counts may experience
convergence of their mortality risk to that of patients with inter-
mediate (200–349 cells/µL) or high (≥500 cells/µL) baseline CD4
count, from 5 years after the start of treatment. As expected, Ta
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associations of baseline CD4 count with mortality were attenuat-
ed after adjusting for other prognostic factors at the time of start-
ing ART. Associations moved away from the null after further
adjusting for background mortality in relative survival models,
but this did not impact our results substantially.
The importance of CD4 count nadir as a prognostic factor for
survival in HIV-infected individuals starting ART is well estab-
lished [3]. However, the extent to which patients with low base-
line CD4 count surviving the ﬁrst years of treatment remain at
an increased risk of death, compared to patients starting with
higher baseline CD4 counts, has remained unclear. To our
knowledge, our study is the ﬁrst to demonstrate that patients
who started treatment in later stages of HIV disease may expect
their mortality risk to become similar to that of patients starting
treatment with higher CD4 counts, if they survive the ﬁrst 5
years of therapy. The majority of patients (85.7% [95% CI,
85.2%–86.3%]) who started ART with CD4 count <200 cells/
µL in this cohort collaboration do indeed survive 5 years.
This is an important message for patients and physicians
alike, as the moving from a higher- to a lower-risk group
through long-term treatment adherence may be a powerful mo-
tivator. Our ﬁndings are consistent with previous studies which
showed that current CD4 count is more important than baseline
CD4 count [5, 6].
For the ﬁrst 5 years of ART, there was a graded inverse rela-
tionship between baseline CD4 count and mortality, which was
consistent with our previous ﬁndings [12].After 5 years of ART,
>15% of the patients with a baseline CD4 count of <50 cells/µL
had died. These results are consistent with the rate of immuno-
logical nonresponders to ART previously observed [13, 14]. Pa-
tients with poor immunological response or multiple AIDS or
non-AIDS morbidity continue to have a substantially increased
mortality ratio after 3 years of treatment [14, 15]. A low CD4
nadir is not only an established risk factor for death, but also
for poor CD4 recovery [16–18]. This may reach a plateau
after about 2 years of ART [18], although a very recent analysis
indicates slow but steady long-term recovery of CD4 counts
under continued treatment [15].
These ﬁndings raise the question of how to identify patients
at high risk of mortality during the ﬁrst 5 years of ART and what
Table 3. Crude and Adjusted Associations of CD4 Cell Count at Start of Antiretroviral Therapy (ART) With Mortality at Increasing Durations Since Start of
ART
Duration of ART, y
CD4 Count, Cells/µL
0–49 50–99 100–199 200–349 350–499 ≥500
n = 6512 (1654
Deaths)
n = 3766 (844
Deaths)
n = 6799 (1292
Deaths)
n = 9633 (1338
Deaths)
n = 5990 (697
Deaths)
n = 4796 (519
Deaths)
Crude MRR (95% CI)
<0.5 5.51 (4.26–7.12) 2.92 (2.14–3.99) 2.22 (1.66–2.97) 1 0.63 (.41–.96) 0.53 (.32–.87)
0.5–0.9 3.47 (2.57–4.68) 2.71 (1.91–3.84) 1.92 (1.38–2.67) 1 0.56 (.34–.91) 0.32 (.17–.63)
1–2.9 2.85 (2.42–3.36) 2.16 (1.78–2.63) 1.72 (1.44–2.06) 1 0.69 (.54–.86) 0.67 (.51–.87)
3–4.9 1.72 (1.45–2.05) 1.55 (1.26–1.90) 1.34 (1.12–1.61) 1 0.78 (.63–.97) 0.65 (.51–.84)
5–9.9 1.17 (1.02–1.34) 1.42 (1.22–1.65) 1.30 (1.15–1.49) 1 0.92 (.80–1.07) 0.83 (.71–.98)
≥10 1.03 (.84–1.25) 1.31 (1.05–1.64) 1.17 (.97–1.42) 1 0.84 (.68–1.03) 0.98 (.79–1.21)
All time 1.87 (1.74–2.02) 1.69 (1.55–1.84) 1.44 (1.33–1.55) 1 0.81 (.74–.89) 0.77 (.69–.85)
Adjusted MRR (95% CI)
<0.5 2.81 (2.12–3.71) 1.71 (1.24–2.37) 1.67 (1.25–2.25) 1 0.70 (.46–1.07) 0.62 (.38–1.02)
0.5–0.9 2.50 (1.80–3.47) 2.04 (1.41–2.93) 1.65 (1.18–2.31) 1 0.59 (.36–.96) 0.35 (.18–.69)
1–2.9 2.33 (1.95–2.79) 1.76 (1.44–2.16) 1.53 (1.28–1.83) 1 0.72 (.57–.91) 0.72 (.55–.94)
3–4.9 1.59 (1.31–1.92) 1.36 (1.10–1.69) 1.22 (1.02–1.47) 1 0.80 (.64–1.00) 0.70 (.55–.91)
5–9.9 1.01 (.87–1.17) 1.20 (1.02–1.40) 1.16 (1.02–1.32) 1 0.96 (.83–1.11) 0.92 (.78–1.08)
≥10 0.85 (.68–1.05) 1.07 (.85–1.35) 1.01 (.83–1.22) 1 0.88 (.71–1.09) 1.09 (.88–1.35)
All time 1.51 (1.40–1.64) 1.37 (1.25–1.50) 1.26 (1.16–1.36) 1 0.85 (.78–.93) 0.84 (.76–.93)
Adjusted relative MRR (95% CI)
<0.5 3.15 (2.28–4.36) 1.87 (1.29–2.72) 1.84 (1.31–2.59) 1 0.66 (.39–1.11) 0.52 (.27–1.02)
0.5–0.9 2.91 (1.97–4.31) 2.38 (1.55–3.65) 1.80 (1.20–2.70) 1 0.46 (.22–.94) 0.30 (.12–.75)
1–2.9 2.78 (2.23–3.48) 2.01 (1.57–2.58) 1.66 (1.32–2.09) 1 0.65 (.47–.91) 0.65 (.45–.93)
3–4.9 1.74 (1.39–2.20) 1.42 (1.09–1.85) 1.31 (1.04–1.63) 1 0.78 (.59–1.03) 0.63 (.45–.90)
5–9.9 0.99 (.81–1.21) 1.27 (1.03–1.56) 1.20 (1.00–1.43) 1 0.94 (.77–1.14) 0.79 (.63–1.00)
≥10 0.79 (.55–1.15) 0.98 (.65–1.47) 1.01 (.73–1.40) 1 0.79 (.55–1.14) 1.12 (.79–1.58)
All time 1.72 (1.56–1.91) 1.51 (1.35–1.70) 1.35 (1.22–1.50) 1 0.80 (.70–.91) 0.75 (.64–.86)
The relative survival model accounts for age-, sex-, and country-matched population mortality.Models were stratified by cohort. Adjusted and relative survival models were adjusted for sex, age,
transmission risk group, AIDS at baseline, viral load, and year of starting ART.
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; MRR, mortality rate ratio.
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strategies could reduce this risk. These could include screening
programs and intensive adherence counseling. A previous study
demonstrated that patients with a CD4 count<200 cells/µL at
baseline are at a higher risk for AIDS in particular, but also
for non-AIDS-related mortality [12]. In that study, malignan-
cies and infections were the primary causes of death, and
both occurred more frequently in patients with a CD4 count
<200 cells/µL. The observed convergence of survival rates
after 5 years may be partly explained by the early death of
patients with low to very low baseline CD4 count, especially im-
munological nonresponders, whereas others gradually achieve
immunological recovery. The suggestion of a lower risk among
those who started ART with very low compared with interme-
diate CD4 count after 10 years may reﬂect a cohort of survivors
who are adherent and respond well to therapy, but is also con-
sistent with a chance ﬁnding.
We analyzed large numbers of patients from high-quality clin-
ical cohorts. We obtained more accurate comparisons by using
relative survival models that adjust for both patient characteristics
and the background age, sex, and country general population
mortality. Adjusting associations of CD4 count with mortality
for age and sex as covariates in a conventional analysis that
only considers mortality of those with HIV infection may be in-
ducing bias toward the null. Although additionally adjusting for
background mortality increased associations of baseline CD4
count with both cumulative mortality and early mortality, it
did not affect our conclusions about the convergence of mortality
in those who survived 5 years from starting ART.
Our study has some limitations. We chose patients starting
ART between 1996 and 2001 to allow ≥10 years of follow-up
for each person included. Whereas only such patients have
been treated with long-term ART, newer drugs that have been in-
troduced since 2002 are associated with better immune recovery
[19] and/or CD4 recovery in immunological nonresponders [19–
21], compared with drugs on which the patients in our study
started combination ART. More second-line treatment options
and new formulations with improved convenience have become
available, allowing better treatment adherence and successful
treatment of drug-resistant infections. Therefore, patients across
all baseline CD4 count strata are likely to experience lower mor-
tality than that of the patients included in our study.
While we included a broad range of patients with different
risk factors from Europe and North America, generalizability
to patients treated in other settings may be limited. Our results
may be biased by loss to follow-up. Although loss to follow-up
rates were high, cohorts have good ascertainment of death pro-
cedures and it is therefore more likely that patients transferred
care to another center not in ART-CC or dropped out of care,
rather than died [22]. However, our results should be generaliz-
able to individuals remaining in HIV care. The high death rate
observed in patients with unknown risk transmission is linked
to the high death rate in older patients because risk group was
poorly recorded in cohorts that included more patients aged
>60 years. Data on non-HIV-related factors (eg, socioeconomic
disadvantage or lifestyle risk factors) were not available, but
may have contributed to excess mortality during the ﬁrst 5
years of treatment in patients with low baseline CD4 counts.
In conclusion, CD4 count at start of ART strongly predicts
MRs during the ﬁrst 5 years of ART. This ﬁnding reinforces
the need for earlier diagnosis and treatment of people living
with HIV. However, there is little evidence that CD4 count at
start of ART predicts mortality after 5 years of ART. This is a
positive message for patients: The burden of increased mortality
associated with starting treatment late is alleviated for those
who survive 5 years on ART.
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